ICOS: Added Heart Protection with NLA & AHA-Recommended Dyslipidemia Therapy
ICOS: Added Heart Protection with NLA & AHA-Recommended Dyslipidemia Therapy
For adults on maximally tolerated statins with TG ≥150 mg/dL and established CVD or diabetes and ≥2 CVD risk factors*
Icosapent Ethyl
WITH RECOMMENDATIONS FROM
IPE recommended as First-Line Therapy for patients with T2DM and CADwhose triglycerides remain elevated (>135 mg/dL) despite maximally tolerated statin and lifestyle changes.1
IPE recommended as Class I, Level B-R Strong Recommendation for high-risk and very-high-risk patients with TG 135-499 mg/dL on statin therapy.2
To explore how ICOS can assist your CV patients and connect you with a medical rep, please tick the box below:
IPE: Icosapent ethyl; AHA: American Heart Association (AHA) Science Advisory 2020; NLA: National Lipid Association (NLA) Scientific Statement 2019; T2DM: Type 2 diabetes; CAD: Coronary Artery Disease; TG: Triglyceride; CVD: Cardiovascular Diseases; CV: Cardiovascular; LDL-C: Low-density lipoprotein-cholesterol
GGI-CO-A1-AQS-300040480-ELC-H24-1443
References:
1.
Arnold SV, Bhatt DL, Barsness GW, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020;141(19):e779-e806.
2.
Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860-872.
*Prescribing information of ICOS, generated & latest modified on June 2023
